Faron Pharmaceuticals
1.786
EUR
-0.45 %
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
4,917 following
-0.45%
-6.49%
-29.13%
-14.95%
-38.31%
-52.63%
-42.01%
-55.29%
-
-48.68%
www.faron.com/investors
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreP/E (adj.) (24e)
-6.29
EV/EBIT (adj.) (24e)
-7.31
P/B (24e)
-18.28
Dividend yield-% (24e)
-
Target price
2.80 EUR
Recommendation
Accumulate
Updated
28.8.2024
First North Finland
FARON
Daily low / high price
1.76 / 1.85
EUR
Market cap
186.86M EUR
Turnover
315.16K EUR
Volume
173K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analyst
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 |
| growth-% | 86,030.6 % | |||||||
| EBITDA | -16.4 | -20.8 | -27.4 | -28.2 | -25.7 | -29.0 | -30.3 | -27.6 |
| EBIT (adj.) | -16.7 | -21.1 | -27.4 | -28.6 | -26.1 | -29.2 | -30.5 | -27.8 |
| EBIT | -16.7 | -21.1 | -27.4 | -28.6 | -26.1 | -29.2 | -30.5 | -27.8 |
| Profit before taxes | -16.9 | -21.2 | -28.7 | -30.9 | -29.7 | -31.2 | -32.7 | -30.2 |
| Net income | -16.9 | -21.2 | -28.6 | -30.9 | -29.7 | -31.2 | -32.7 | -30.2 |
| EPS (adj.) | -0.36 | -0.40 | -0.48 | -0.45 | -0.28 | -0.30 | -0.31 | -0.29 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -409,275.0 % | -520,050.0 % | -685,675.0 % | -705,550.0 % | -643,250.0 % | -725,782.5 % | -758,350.0 % | -801.6 % |
| EBIT-% (adj.) | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -653,250.0 % | -730,500.0 % | -762,390.0 % | -805.6 % |
| EBIT-% | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -653,250.0 % | -730,500.0 % | -762,390.0 % | -805.6 % |
| ROE | 14,063.1 % | -3,920.3 % | 670.4 % | 232.3 % | 234.3 % | 120.9 % | 56.6 % | 33.8 % |
| ROI | -676.3 % | -588.9 % | -707.3 % | 7,250.8 % | 3,960.6 % | -3,336.9 % | -4,042.5 % | -4,212.1 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 2.91 | 3.24 | 3.71 | 3.77 | 1.79 | 1.79 | 1.79 | 1.79 |
| Shares | 46.9 | 53.2 | 59.8 | 68.8 | 104.6 | 104.6 | 104.6 | 104.6 |
| Market cap | 136.5 | 172.5 | 221.6 | 259.3 | 186.9 | 186.9 | 186.9 | 186.9 |
| Enterprise value | 135.1 | 169.0 | 227.5 | 265.3 | 191.0 | 222.1 | 254.7 | 284.8 |
| EV/S | 33,775.4 | 42,241.4 | 56,880.5 | 66,337.2 | 47,755.7 | 55,526.8 | 63,674.0 | 82.7 |
| EV/EBITDA | - | - | - | - | - | - | - | - |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
| EV/EBIT | - | - | - | - | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | - | 58.8 | - | - | - | - | - | - |
| P/S | 34,117.3 | 43,117.9 | 55,389.8 | 64,831.5 | 46,714.6 | 46,714.6 | 46,714.6 | 54.2 |
| Dividend yield | ||||||||
| Equity ratio | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -97.9 % | -402.0 % | -726.8 % | -1,031.1 % |
| Gearing ratio | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -40.7 % | -85.1 % | -91.5 % | -93.9 % |
Quarter data
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | |||||
| EBITDA | -15.6 | -28.2 | -11.1 | -14.6 | -25.7 | ||||
| EBIT | -15.8 | -28.6 | -11.3 | -14.8 | -26.1 | ||||
| Profit before taxes | -17.2 | -30.9 | -14.4 | -15.3 | -29.7 | ||||
| Net income | -17.2 | -30.9 | -14.4 | -15.3 | -29.7 |
ShowingAll content types
Faron Pharmaceuticals Oy: Composition of Faron Pharmaceutical's Shareholders' Nomination Board
Faron Pharmaceuticals Capital Markets Day 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Faron Pharmaceuticals Oy: Faron's Capital Markets Day 2024
Faron Pharmaceuticals Oy: Faron announces Capital Markets Day
Probabilities of success in drug development
Clinical phases of drug development
Faron Pharmaceuticals Oy: Grant of options
Faron Pharmaceuticals, Q2'24
Redeye: Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead
Faron Pharmaceuticals Oy: Faron 2024 Half-Year Financial Results
Faron Pharmaceuticals Oy: FDA Grants Fast Track Designation for Bexmarilimab
Faron Pharmaceuticals Oy: Notice of Half-Year Financial Results
Faron Pharmaceuticals Oy: Traumakine Research Collaboration and DoD Grant
Faron Pharmaceuticals Oy: Appointment of Chief Financial Officer
Faron Pharmaceuticals Oy: Grant of options
Faron Pharmaceuticals Oy: Faron Appoints Dr. Petri Bono as new CMO
